Receptor Therapeutics Inc. – a MaRS tenant – has raised $500,000 from the OICR’s IPDC Program via its OncoTek Drug Delivery Inc. subsidiary.
The funds will be used to drive the preclinical development of the company’s PoLi-PTX technology – a drug delivery system for intraperitoneal ovarian cancer. PoLi-PTX is intended to permit effective localized cancer therapy without the associated side-effects of traditional chemotherapy.
Read the news release here (PDF).
Congratulations!